US EditionAfrica: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
3 Articles
3 Articles
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system
Human endogenous retroviruses (HERVs) are remnants of ancestral infections and chromosomally integrated in all cells of an individual, are transmitted only vertically and are defective in viral replication. However enhanced expression of HERV-K accompanied by the emergence of anti-HERV-K-directed immune responses has been observed inter-alia in HIV-infected individuals and tumor patients. Therefore HERV-K might serve as a tumor-specific antigen …
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
